COLO B Coloplast A/S Class B

Coloplast A/S - Announcement no. 07/2020 - Coloplast strengthens Executive Management

Coloplast A/S - Announcement no. 07/2020 - Coloplast strengthens Executive Management

Coloplast strengthens Executive Management to deliver on upcoming 2025 strategy centred around innovation and growth

Today, the Board of Directors have decided to expand the Executive Leadership Team from four members to six members as of 1 October 2020.

The expansion aims to support the upcoming strategy which will focus on innovation and growth. A new Innovation Executive Vice President position position with responsibility for the company’s commercial offering and combining marketing, R&D and select global functions will be led by Nicolai Buhl Andersen. A new Growth Executive Vice President position position which combines the chronic care sales organization and the Wound & Skin care SBU will be led by Paul Marcun. Finally, HR is renamed People & Culture and elevated to the Executive leadership team to be led by Camilla G. Møhl.

Nicolai Buhl Andersen is appointed Executive Vice President, Innovation and member of the Executive Leadership Team. Since joining Coloplast in 2005, Nicolai has held various senior management roles in the company including Head of Ostomy Care, Head of Sales, Nordic Region and Commercial Excellence. For the last 10 years, Nicolai has been SVP, Global Wound Care. Nicolai holds a Master's degree in Economics and Marketing from Copenhagen Business School and Sophia University, Japan.

Camilla G. Møhl is appointed Senior Vice President, People & Culture and member of the Executive Leadership Team. Since joining Coloplast in 2016, Camilla has been VP, Global HR Commercial Organization and was promoted to VP Global HR in 2019. Prior to joining Coloplast, Camilla gained more than 15 years’ experience within HR at large international companies including Carlsberg and Mars. Camilla holds a Master’s degree in Human Resources Management from Copenhagen Business School.

“We are currently in the process of finalising our 2025 strategy, which will be launched at our Capital Markets Day at the end of September. As we look towards 2025, and strive to continue to deliver value for our shareholders, users, employees, healthcare professionals and partners, Innovation and Growth will be key strategic themes. To set ourselves up to deliver on our 2025 strategy, we’ve decided to expand our Executive Leadership Team and create new roles to match these strategic themes. I am happy to welcome Nicolai and Camilla to the team. Strong, passionate leaders, with strong followership, who live and breathe the Coloplast values,” says President & CEO Kristian Villumsen.

“By expanding the Coloplast Executive Leadership Team, we are taking the first steps to secure a successful execution of the company’s 2025 strategy. Innovation and growth have characterised Coloplast for more than 60 years, and I am confident that this leadership team is well-equipped to deliver solid growth and life-changing innovations in the years to come,” says Chairman Lars Rasmussen.

As of 1 October 2020, the Executive Leadership Team will consist of:

President & CEO, Kristian Villumsen

Executive Vice President, Innovation, Nicolai Buhl Andersen

Executive Vice President & CFO, Anders Lonning-Skovgaard

Executive Vice President, Growth, Paul Marcun

Senior Vice President, People & Culture, Camilla G. Møhl

Executive Vice President, Global Operations, Allan Rasmussen

Lars Rasmussen

Chairman of the Board 



For more information, please contact:

Investors and analysts

Anders Lonning-Skovgaard

Executive Vice President, CFO

Tel.

Ellen Bjurgert

Vice President, Investor Relations

Tel. / 4911 3376

E-mail

Rasmus Sørensen

Senior Manager, Investor Relations

Tel. / 4911 1786

E-mail

Press and the media

Lina Danstrup

Senior Media Relations Manager, Corporate Communications

Tel.

E-mail

Website

Address

Coloplast A/S

Holtedam 1

DK-3050 Humlebæk

Denmark

Business reg. (CVR) no. 69749917 

This announcement is available in a Danish and an English-language version. In the event of discrepancies, the Danish version shall prevail.

Coloplast develops products and services that make life easier for people with very personal and private medical conditions. Working closely with the people who use our products, we create solutions that are sensitive to their special needs. We call this intimate healthcare. Our business includes Ostomy Care, Continence Care, Wound and Skin Care and Interventional Urology. We operate globally and employ about 12,000 employees.

The Coloplast logo is a registered trademark of Coloplast A/S. © 2020-08.

All rights reserved Coloplast A/S, 3050 Humlebaek, Denmark.

Attachment

EN
18/08/2020

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Coloplast A/S Class B

Coloplast AS: 1 director

A director at Coloplast AS bought 2,150 shares at 463.200DKK and the significance rating of the trade was 54/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly ...

 PRESS RELEASE

Coloplast A/S - Bestyrelsesmedlemmers, direktørers eller nærtstående p...

Coloplast A/S - Bestyrelsesmedlemmers, direktørers eller nærtstående personers handel med Coloplast-aktier Se venligst vedlagte pdf.   Vedhæftet fil

 PRESS RELEASE

Coloplast A/S - Trading in Coloplast shares by board members, executiv...

Coloplast A/S - Trading in Coloplast shares by board members, executives or associated persons Please see enclosed pdf.   Attachment

 PRESS RELEASE

Coloplast udnævner Gavin Wood som ny CEO

Coloplast udnævner Gavin Wood som ny CEO Selskabsmeddelelse nr. 3/2026 Intern viden Coloplast udnævner Gavin Wood som ny CEO Det er med glæde, at Coloplasts bestyrelse kan annoncere udnævnelsen af Gavin Wood som ny CEO fra den 1. maj 2026. Gavin Wood afløser Lars Rasmussen, der har været midlertidig CEO siden den 5. maj 2025. Gavin Wood har i to årtier bestredet forskellige ledelsesroller i Johnson & Johnson, senest som øverste leder for Johnson & Johnson MedTech EMEA, en forretning der omsætter for adskillige milliarder dollars og har mere end 7000 medarbejdere på tværs af tre forretnin...

 PRESS RELEASE

Coloplast appoints Gavin Wood as new CEO

Coloplast appoints Gavin Wood as new CEO Announcement no. 3/2026 Inside information Coloplast appoints Gavin Wood as new CEO The Coloplast Board of Directors is pleased to announce the appointment of Gavin Wood as the new President and Chief Executive Officer (CEO) of the Coloplast Group, effective May 1, 2026. Gavin Wood will take over from interim CEO Lars Rasmussen, who has been in the role since May 5, 2025. Gavin Wood has spent two decades in different leadership roles in Johnson & Johnson, most recently as Company Group Chairman of Johnson & Johnson MedTech EMEA, a multi-billion-do...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch